TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 261957

Group type: EXPERIMENTAL
Intervention: Metoprolol (150 mg/die)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31424568

Group type: COMPARATOR
Intervention: 5FU/LV
Number of subjects: 4949

Group type: COMPARATOR
Intervention: FOLFOX
Number of subjects: 4949

Group type: COMPARATOR
Intervention: Any adjuvant treatment
Number of subjects: 4949
Study: 30502501

Group type: EXPERIMENTAL
Intervention: Internet-CBT
Number of subjects: 90
Study: 28341243

Group type: EXPERIMENTAL
Intervention: Non-preserved gel solution of carboxymethylcellulose
Number of subjects: 2

Group type: COMPARATOR
Intervention: Non-preserved saline
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 2
Study: 25813300

Group type: EXPERIMENTAL
Intervention: P6 stimulation
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no P6 stimulation)
Number of subjects: 56
Study: 23691829

Group type: EXPERIMENTAL
Intervention: Implicit learning in a simulated environment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Articulatory suppression (affecting working memory)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training in the simulated environment
Number of subjects: 0
Study: 21642529

Group type: EXPERIMENTAL
Intervention: Interactive dental video game teaching the three‐step etch‐and‐rinse resin bonding system
Number of subjects: 80

Group type: COMPARATOR
Intervention: Clinical video recording of the three‐step etch‐and‐rinse resin bonding system
Number of subjects: 80
Study: 19500003

Group type: EXPERIMENTAL
Intervention: Powdered Nigella sativa (Kalonji) seed in capsules
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 16458688

Group type: EXPERIMENTAL
Intervention: Sovereign with WhiteStar (SWS) system
Number of subjects: 26

Group type: COMPARATOR
Intervention: Legacy with AdvanTec and NeoSoniX (LAD) system
Number of subjects: 26

Group type: COMPARATOR
Intervention: Legacy with AdvanTec and NeoSoniX (LAD) system (cataract density of 4)
Number of subjects: 26
Study: 14984521

Group type: EXPERIMENTAL
Intervention: PEEP group (n = 20) - pre-oxygenated using 100% O2 with CPAP (6 cmH2O) for 5 min, followed by mechanical ventilation with PEEP 6 cm H2O for 5 min
Number of subjects: 40

Group type: COMPARATOR
Intervention: ZEEP group (n = 20) - no CPAP or PEEP used
Number of subjects: 40
Study: 10051763

Group type: EXPERIMENTAL
Intervention: Buprenorphine (partial opioid agonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naloxone (10 mg)
Number of subjects: 0
Study: 7747291

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 400 mg every 12 h for 3 days
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Erythromycin 500 mg every 6 h for 3 days
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Nalidixic acid 500 mg every 6 h for 3 days
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Pivmecillinam 500 mg every 6 h for 3 days
Number of subjects: 75

Group type: COMPARATOR
Intervention: Tetracycline (control group)
Number of subjects: 75
Study: 2106804

Group type: EXPERIMENTAL
Intervention: Ranitidine boluses
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Continuous ranitidine infusions
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Continuous ranitidine infusions with enteral nutrition via nasogastric tube
Number of subjects: 22

Group type: COMPARATOR
Intervention: Other therapeutic regimens (pirenzepine and sucralfate)
Number of subjects: 22
Study: 6991105

Group type: EXPERIMENTAL
Intervention: Levamisole immunotherapy
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 31744401

Group type: EXPERIMENTAL
Intervention: 3% rapid weight loss (RWL)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control
Number of subjects: 9
Study: 31888511

Group type: EXPERIMENTAL
Intervention: Videolaryngoscope-guided technique
Number of subjects: 119

Group type: COMPARATOR
Intervention: Standard digital technique
Number of subjects: 119
Study: 27469537

Group type: EXPERIMENTAL
Intervention: 1 hand therapy visit at 10-14 days postoperatively
Number of subjects: 134
Study: 24614837

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) 100 mg/kg/day
Number of subjects: 80
Study: 22293678

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Passive warm-up (PW)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 6
Study: 19818450

Group type: EXPERIMENTAL
Intervention: 0.45% saline solution at 100% maintenance rate
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: 0.45% saline solution at 50% maintenance rate
Number of subjects: 124

Group type: COMPARATOR
Intervention: 0.9% saline solution at 100% maintenance rate
Number of subjects: 124

Group type: COMPARATOR
Intervention: 0.9% saline solution at 50% maintenance rate
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Fluid type (0.45% vs 0.9% saline)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Fluid administration rate
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: 100% maintenance rate
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: 50% maintenance rate
Number of subjects: 124
Study: 16954337

Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme substitution (PES)
Number of subjects: 8
Study: 15694213

Group type: EXPERIMENTAL
Intervention: IMPACT intervention (multidisciplinary depression treatment program with care manager support)
Number of subjects: 1801

Group type: EXPERIMENTAL
Intervention: IMPACT intervention
Number of subjects: 1801

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1801
Study: 12001042

Group type: EXPERIMENTAL
Intervention: Simplified regimen of abacavir-lamivudine-zidovudine (n=84)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Continuation with protease inhibitor plus nucleoside-analogue combination regimens (n=79)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Simplified regimen of abacavir-lamivudine-zidovudine
Number of subjects: 163
Study: 10190835

Group type: EXPERIMENTAL
Intervention: Ad lib feeding regimen
Number of subjects: 78

Group type: COMPARATOR
Intervention: Prescribed feeding regimen
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 20-calorie formula
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 24-calorie formula
Number of subjects: 78
Study: 7768298

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (200 micrograms) administered twice daily for 2 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: House dust mite extract nasal challenge
Number of subjects: 24
Study: 2180106

Group type: EXPERIMENTAL
Intervention: Oral prednisolone 40 mg per day for 14 days
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate 500 micrograms thrice daily for 14 days
Number of subjects: 121

Group type: COMPARATOR
Intervention: Withdrawal of treatment
Number of subjects: 121
Study: 7256808

Group type: EXPERIMENTAL
Intervention: Combined radiotherapy schemes (external and intracavitary radiations given alternately with unequal doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified approximate CRE and nominal dose methods
Number of subjects: 0
Study: 31506096

Group type: EXPERIMENTAL
Intervention: Simultaneously increase exercise and fruit/vegetable intake, while decreasing sedentary leisure screen time
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Sequentially increase fruit/vegetable intake and decrease leisure screen time first, then increase exercise
Number of subjects: 340

Group type: COMPARATOR
Intervention: Increase sleep and decrease stress (control)
Number of subjects: 340
Study: 28526493

Group type: EXPERIMENTAL
Intervention: CAREFuL (Care Programme for the Last Days of Life)
Number of subjects: 451

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 451
Study: 26068140

Group type: EXPERIMENTAL
Intervention: Remote follow-up (telephone follow-up with serum β‐hCG and symptom checklist)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Standard in-clinic follow-up (ultrasound and assessment)
Number of subjects: 129
Study: 24526708

Group type: EXPERIMENTAL
Intervention: Peroneal nerve functional electrical stimulation (FES)
Number of subjects: 495

Group type: COMPARATOR
Intervention: Ankle-foot orthosis (AFO)
Number of subjects: 495
Study: 22211512

Group type: EXPERIMENTAL
Intervention: Supervised, progressive resistance and functional group training for 3 months (intervention group, n=62)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Low-intensity motor placebo activity (control group, n=60)
Number of subjects: 122
Study: 18036144

Group type: EXPERIMENTAL
Intervention: 0.9% saline (normal saline)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 4% dextrose and 0.18% saline (dextrose saline)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Full maintenance rate
Number of subjects: 50

Group type: COMPARATOR
Intervention: Restricted rate
Number of subjects: 50
Study: 17531931

Group type: EXPERIMENTAL
Intervention: Amlodipine +/‐ perindopril
Number of subjects: 159

Group type: COMPARATOR
Intervention: Atenolol +/‐ bendroflumethiazide
Number of subjects: 159
Study: 16945514

Group type: EXPERIMENTAL
Intervention: 5 mL/kg of pentastarch (group A)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 10 mL/kg of pentastarch (group B)
Number of subjects: 70
Study: 15156783

Group type: EXPERIMENTAL
Intervention: Patients with unilateral hemispheric infarcts (with or without neglect)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with hemispatial neglect
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with hemianopia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with right-hemisphere lesions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 0
Study: 10987233

Group type: EXPERIMENTAL
Intervention: Postmastectomy radiotherapy and systemic treatment
Number of subjects: 84

Group type: COMPARATOR
Intervention: Systemic treatment alone
Number of subjects: 84
Study: 8800358

Group type: EXPERIMENTAL
Intervention: 4% CO2 inhalation during exhaustive maximal two‐legged cycling
Number of subjects: 5

Group type: COMPARATOR
Intervention: No CO2 inhalation during exhaustive maximal two‐legged cycling
Number of subjects: 5
Study: 1815226

Group type: EXPERIMENTAL
Intervention: Arginine-vasopressin (AVP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 6336641

Group type: EXPERIMENTAL
Intervention: Bicozamycin (500 mg orally four times daily for 3 days)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Bicozamycin
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 31136456

Group type: EXPERIMENTAL
Intervention: Pediatric resuscitation
Number of subjects: 37

Group type: COMPARATOR
Intervention: Adult resuscitation
Number of subjects: 37
Study: 31689072

Group type: EXPERIMENTAL
Intervention: XylS mutants recognizing p-toluic acid; specific mutations include T74P and N7R.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual selection system for directed evolution of XylS.
Number of subjects: 0
Study: 29265040

Group type: EXPERIMENTAL
Intervention: Pharmaceutical Care Group (PC)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual Care Group (UC)
Number of subjects: 200
Study: 27124825

Group type: EXPERIMENTAL
Intervention: Integrated 2‐screw cephalomedullary nail (InterTan)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Single-screw device (Gamma3)
Number of subjects: 104
Study: 24400655

Group type: EXPERIMENTAL
Intervention: Alogliptin plus Metformin (A+M) 12.5/500 mg BID
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Alogliptin plus Metformin (A+M) 12.5/1000 mg BID
Number of subjects: 784

Group type: COMPARATOR
Intervention: Alogliptin (A) 12.5 mg BID
Number of subjects: 784

Group type: COMPARATOR
Intervention: Metformin (M) 500 mg BID
Number of subjects: 784

Group type: COMPARATOR
Intervention: Metformin (M) 1000 mg BID
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Alogliptin plus Metformin (A+M)
Number of subjects: 784

Group type: COMPARATOR
Intervention: Alogliptin (A) and Metformin (M) monotherapies
Number of subjects: 784
Study: 22932329

Group type: EXPERIMENTAL
Intervention: Bipolar coagulation therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Crescent conjunctival resection
Number of subjects: 60
Study: 19772761

Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei strain KW3110
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 17273815

Group type: EXPERIMENTAL
Intervention: Prosthetic repair (onlay polypropylene mesh)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Tissue repair
Number of subjects: 42
Study: 15149251

Group type: EXPERIMENTAL
Intervention: Task span procedure with lists of 1-10 task names and stimuli to perform tasks.
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Practice with consistent and varied lists.
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Manipulation of the number of task switches.
Number of subjects: 70
Study: 11403192

Group type: EXPERIMENTAL
Intervention: 1% cidofovir cream
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9557925

Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 12
Study: 7999500

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Tracheal intubation
Number of subjects: 2
Study: 3386087

Group type: EXPERIMENTAL
Intervention: Cisapride 15 mg/day
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cisapride 7.5 mg/day
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31502420

Group type: EXPERIMENTAL
Intervention: Muse
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: DayDream
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Wild Divine
Number of subjects: 15
Study: 31048758

Group type: COMPARATOR
Intervention: ADM AG genotype (vs. ADM GG genotype) in boys
Number of subjects: 675

Group type: COMPARATOR
Intervention: ADM AG+AA genotype (vs. ADM GG genotype) in boys
Number of subjects: 675

Group type: COMPARATOR
Intervention: ADM AG genotype (vs. ADM GG+AA genotype) in boys
Number of subjects: 675

Group type: COMPARATOR
Intervention: ADM AG+AA genotype (vs. ADM GG genotype) in girls
Number of subjects: 675

Group type: EXPERIMENTAL
Intervention: ADM gene polymorphism
Number of subjects: 675
Study: 28604375

Group type: EXPERIMENTAL
Intervention: Le Fort I osteotomy leaving in situ the wisdom upper third molars (Group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Le Fort I osteotomy after extraction of the wisdom upper third molars (Group B)
Number of subjects: 20
Study: 25534294

Group type: EXPERIMENTAL
Intervention: Nintedanib plus docetaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus docetaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 0
Study: 23412024

Group type: EXPERIMENTAL
Intervention: Mindfulness-based psychoeducation program
Number of subjects: 96

Group type: COMPARATOR
Intervention: Usual psychiatric care
Number of subjects: 96
Study: 21421952

Group type: EXPERIMENTAL
Intervention: Exposure to Above the Influence antidrug advertisements
Number of subjects: 0
Study: 19120074

Group type: EXPERIMENTAL
Intervention: Antiviral therapy (Ganciclovir and valganciclovir) for 3 weeks
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Antiviral therapy (Ganciclovir and valganciclovir)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: HHV‐6 co-infection
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: HHV‐7 co-infection
Number of subjects: 256
Study: 17805109

Group type: EXPERIMENTAL
Intervention: Intraoperative topical Sensorcaine
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 37
Study: 14754739

Group type: EXPERIMENTAL
Intervention: EndoPearl adjunct to bioabsorbable interference screw fixation
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 35
Study: 12452980

Group type: EXPERIMENTAL
Intervention: Tacrolimus (FK506)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Cyclosporin
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Cyclosporin plus Nifedipine
Number of subjects: 79
Study: 10999089

Group type: EXPERIMENTAL
Intervention: benidipine 4 mg/day
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: benidipine 8 mg/day
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: benidipine 4-8 mg/day
Number of subjects: 34
Study: 7482166

Group type: EXPERIMENTAL
Intervention: Laparoscopic mesh hernia repair
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Open mesh hernia repair
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Bassini repair
Number of subjects: 34
Study: 2271468

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 44
Study: 7007454

Group type: COMPARATOR
Intervention: 5 mg folate tablets (Group B)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Folate mouthwash (Group C)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo mouthwash and tablets (Group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo mouthwash and 5 mg folate tablets (Group B)
Number of subjects: 30
Study: 31796533

Group type: EXPERIMENTAL
Intervention: Sentinel node biopsy in addition to inguinofemoral lymphadenectomy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 80
Study: 31152118

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 28759302

Group type: EXPERIMENTAL
Intervention: Clacier™ (0.05% CsA nanoemulsion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Restasis® (conventional emulsion)
Number of subjects: 0
Study: 26053853

Group type: EXPERIMENTAL
Intervention: Low-salt diet (LSD)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Losartan 50 mg/HCTZ 12.5 mg (NLSD)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Irbesartan 150 mg/HCTZ 12.5 mg (NLSD)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Losartan 100 mg (NLSD)
Number of subjects: 180
Study: 23400982

Group type: EXPERIMENTAL
Intervention: BIS-guided anesthesia (maintaining BIS value of 40 to 60)
Number of subjects: 723

Group type: COMPARATOR
Intervention: ETAC-guided anesthesia (age-adjusted minimum alveolar concentration of 0.7 to 1.3)
Number of subjects: 723
Study: 21625788

Group type: EXPERIMENTAL
Intervention: Dietary counseling according to nutritional status
Number of subjects: 315

Group type: COMPARATOR
Intervention: Routine of the health service facility (Control Group)
Number of subjects: 315
Study: 19207096

Group type: EXPERIMENTAL
Intervention: Prulifloxacin
Number of subjects: 0
Study: 17445815

Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 46

Group type: COMPARATOR
Intervention: Operative treatment
Number of subjects: 46
Study: 15558635

Group type: EXPERIMENTAL
Intervention: Negative mood induction (failure on a quiz)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral mood induction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High impulsivity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low impulsivity
Number of subjects: 0
Study: 11447365

Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) supplementation
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 8
Study: 9065680

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 367

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 367
Study: 8419896

Group type: EXPERIMENTAL
Intervention: Left lateral positioning
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Right lateral positioning
Number of subjects: 16

Group type: COMPARATOR
Intervention: Supine positioning
Number of subjects: 16
Study: 3094439

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 0.25 g single dose
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ampicillin 3.5 g plus probenecid 1.0 g
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ampicillin plus probenecid
Number of subjects: 100
Study: 31223624

Group type: EXPERIMENTAL
Intervention: General public awareness of prescription drugs
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: General public awareness of antibiotic use
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: General public awareness of antibiotic resistance (AR)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Awareness of prescription medicine by gender
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Awareness of antibiotic resistance by occupation
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Awareness of prescription medicine by ethnicity
Number of subjects: 1000
Study: 28750585

Group type: EXPERIMENTAL
Intervention: 0.3 g/kg β‐OHB ketone salts
Number of subjects: 10

Group type: COMPARATOR
Intervention: Flavour‐matched placebo
Number of subjects: 10
Study: 26055122

Group type: EXPERIMENTAL
Intervention: Cognitive control training targeting working memory functioning (10 online sessions over 14 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low cognitive load training (active control condition)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive control training
Number of subjects: 0
Study: 22856682

Group type: EXPERIMENTAL
Intervention: Air particle abrasion for five seconds with 50-μm aluminum oxide particles (Groups 1-3)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Acid etching with 10% hydrofluoric acid for 20 seconds (Groups 4-6)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no specific treatment mentioned)
Number of subjects: 18
Study: 21127866

Group type: EXPERIMENTAL
Intervention: a‐PVAM (700‐900‐μm)
Number of subjects: 46

Group type: COMPARATOR
Intervention: TAGM (500‐700‐μm)
Number of subjects: 46
Study: 19151046

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (100-4000 microg)
Number of subjects: 645
Study: 17716364

Group type: EXPERIMENTAL
Intervention: Structured, standardized and comprehensive complex intervention including patient leaflets, documentation booklets, regular monitoring by a trained practice nurse, and tailored structured counselling by GPs.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Structured, standardized and comprehensive complex intervention.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care by GPs with guideline-oriented management and tailored health counselling concept.
Number of subjects: 0